Literature DB >> 20047053

Comparison of early onset breast cancer patients to older premenopausal breast cancer patients.

Dominic Varga1, Jochem Koenig, Kathrin Kuhr, Kathrin Strunz, Verena Geyer, Christian Kurzeder, Ziad Atassi, Maria Blettner, Rolf Kreienberg, Achim Woeckel.   

Abstract

BACKGROUND: The objective of this study was to show differences between breast cancer patients < or =35 and >35 years with regard to tumor characteristics and to present the patient-relevant outcomes overall survival (OAS) and recurrence-free survival (RFS).
METHODS: We analyzed data from 119 women aged 35 years or younger with breast cancer and compared multiple parameters against breast cancer patients between 36 and 55 (n = 1,097), all pre-menopausal. Data were adjusted for tumor characteristics and therapy.
RESULTS: There was no statistically significant difference in tumor size, axillary lymph node involvement, and histological subtypes. On the contrary, grading lymphovascular invasion and receptor negativity showed statistically significant differences. Unadjusted hazard ratio are 2.11 (1.32-3.39) (OAS) and 1.92 (1.35-2.73) (RFS). Multi-adjusted hazard ratio are 2.97 (1.70-5.18) (OAS) and 2.11 (1.42-3.13) (RFS).
CONCLUSIONS: In conclusion, young breast cancer patients still have a poor prognosis. Even after adjustment of the data, OAS and RFS showed a worse prognosis. Normal prognostic factors like tumor size, axillary lymph node involvement, and grading can therefore be not the explanation for the more aggressive disease progress within early onset breast cancer patients.

Entities:  

Mesh:

Year:  2010        PMID: 20047053     DOI: 10.1007/s00404-009-1339-y

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  6 in total

1.  Expression of antigen processing and presenting molecules in brain metastasis of breast cancer.

Authors:  Yan Liu; Yoshihiro Komohara; Natalie Domenick; Masasuke Ohno; Maki Ikeura; Ronald L Hamilton; Craig Horbinski; Xinhui Wang; Soldano Ferrone; Hideho Okada
Journal:  Cancer Immunol Immunother       Date:  2011-11-08       Impact factor: 6.968

2.  Bioinformatic analysis reveals the key pathways and genes in early-onset breast cancer.

Authors:  Chuanlong Cui; Lun Li; Jing Zhen
Journal:  Med Oncol       Date:  2018-04-11       Impact factor: 3.064

3.  High-risk early breast cancer in patients under 40 years of age: Improved clinical outcome with total estrogen blockade and tailored chemotherapy.

Authors:  Francesco Recchia; Giampiero Candeloro; Stefania Discepoli; Marisa Grimaldi; Giovambattista Desideri; Stefano Necozione; Silvio Rea
Journal:  Exp Ther Med       Date:  2010-07-21       Impact factor: 2.447

4.  Atorvastatin facilitates chemotherapy effects in metastatic triple-negative breast cancer.

Authors:  Juan Luis Gomez Marti; Colin H Beckwitt; Amanda M Clark; Alan Wells
Journal:  Br J Cancer       Date:  2021-08-30       Impact factor: 9.075

Review 5.  Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: approaches and application.

Authors:  Rongrong Huang; Zhongsi Chen; Lei He; Nongyue He; Zhijiang Xi; Zhiyang Li; Yan Deng; Xin Zeng
Journal:  Theranostics       Date:  2017-08-18       Impact factor: 11.556

6.  Retrospective analysis of breast cancer prognosis among young and older women in a Brazilian cohort of 738 patients, 1985-2002.

Authors:  Fabiana De Lima Vazquez; Thiago Buosi Silva; René Aloísio Da Costa Vieira; Allini Mafra Da Costa; Cristovam Scapulatempo; José Humberto Tavares Guerreiro Fregnani; Edmundo Carvalho Mauad; Adhemar Longatto; Kari Juhani Syrjänen
Journal:  Oncol Lett       Date:  2016-11-07       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.